This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sai Priya, V. H.
Right arrow Articles by Valluri, V. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sai Priya, V. H.
Right arrow Articles by Valluri, V. L.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, January 2009, p. 111-115, Vol. 16, No. 1
1071-412X/09/$08.00+0     doi:10.1128/CVI.00243-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

In Vitro Levels of Interleukin 10 (IL-10) and IL-12 in Response to a Recombinant 32-Kilodalton Antigen of Mycobacterium bovis BCG after Treatment for Tuberculosis{triangledown}

V. Hari Sai Priya,1 B. Anuradha,1,2 Suman Latha Gaddam,1 Seyed E. Hasnain,3 K. J. R. Murthy,1 and Vijaya Lakshmi Valluri1,2*

Bhagwan Mahavir Medical Research Centre, Hyderabad, Andhra Pradesh, India,1 LEPRA Society—Blue Peter Research Center, Hyderabad, Andhra Pradesh, India,2 Hyderabad Central University, Hyderabad, Andhra Pradesh, India3

Received 1 July 2008/ Returned for modification 19 July 2008/ Accepted 23 October 2008

Cell-mediated immunity plays a major role in conferring protection against tuberculosis (TB) on an individual. It is not known whether the immune status correlates with the bacterial load or whether the immunity improves after treatment. Also, it may be important to monitor treatment by being able to discriminate between active disease and successfully treated TB. The main aim of this study was to investigate the usefulness of a recombinant 32-kDa antigen (r32-kDa Ag) of Mycobacterium bovis BCG (Ag85A-BCG) as a diagnostic marker in patients being treated for TB. Specifically, the in vitro T-cell assays and the release of interleukin-12 (IL-12) (Th1-type cytokine) and IL-10 (Th2-type cytokine) in response to the r32-kDa Ag of BCG were assayed in patients with either pulmonary (sputum positive/negative, n = 74) or extrapulmonary TB (n = 49) and healthy controls. The proliferative responses of stimulated cells at 0, 2 to 4, and 6 months of treatment increased and were highly significant (P < 0.000) compared to the responses in controls. The increase in IL-12 and decrease in IL-10 release suggest that there is cytokine expression modification during different stages of TB, and treatment seems to have an influence on the levels of these cytokines, suggesting an augmentation in the protective responses. The in vitro response to the M. bovis BCG r32-kDa Ag may be useful in monitoring treatment of TB.

* Corresponding author. Mailing address: Immunology and Molecular Biology, LEPRA Society—Blue Peter Research Center, Hyderabad-501301, Andhra Pradesh, India. Phone: 91-40-27264547. Fax: 91-40-27261262. E-mail: vijayavalluri{at}rediffmail.com

{triangledown} Published ahead of print on 5 November 2008.

Clinical and Vaccine Immunology, January 2009, p. 111-115, Vol. 16, No. 1
1071-412X/09/$08.00+0     doi:10.1128/CVI.00243-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»